CTC
VKTX icon

Central Trust Company’s Viking Therapeutics VKTX Stock Holding History

Central Trust Company’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68
Closed -$1.64K – 1491
2025
Q1 		$1.64K Hold
68
– – ﹤0.01% 1341
2024
Q4 		$2.74K Hold
68
– – ﹤0.01% 1282
2024
Q3 		$4.31K Buy
+68
New +$3.99K ﹤0.01% 1167

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Central Trust Company's VKTX Position: Q2 2025 in Review

Central Trust Company sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 68 shares — an estimated $1.64K sold.

Central Trust Company first reported a position in VKTX in Q3 2024 and held it in 3 quarters. The position peaked at $4.31K in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Central Trust Company reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Central Trust Company sold 68 Viking Therapeutics shares in Q2 2025, an estimated $1.64K.
  • Central Trust Company first reported a position in Viking Therapeutics in Q3 2024 and held it in 3 quarters.
  • Central Trust Company's Viking Therapeutics position peaked at $4.31K in Q3 2024.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Central Trust Company's 13F filing for Q2 2025, filed 7 Aug 2025.